Brands Build Ad Spending As Consumer Interest In Private Label Increases
This article was originally published in The Tan Sheet
Executive Summary
Increased ad spending to compete with both branded and private label products led to an average 4% profit margin slip since 2001 for the top 10 OTC drug makers, according to a report released by Kline & Co. Nov. 16
You may also be interested in...
OTC Prices Make PPI-Aspirin Therapy For CVD Cost-Effective – Study
Using proton pump inhibitors to prevent GI bleeding from low-dose aspirin therapy for cardiovascular health is cost-effective only at OTC prices, according to researchers
OTC Prices Make PPI-Aspirin Therapy For CVD Cost-Effective – Study
Using proton pump inhibitors to prevent GI bleeding from low-dose aspirin therapy for cardiovascular health is cost-effective only at OTC prices, according to researchers
Sure Nature Can “Kiss” ImmunaSure Ad Goodbye – NAD
Sure Nature claims its ImmunaSure dietary supplement can help "kiss your cold sores goodbye," but the National Advertising Division does not embrace the pitch